Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4066 AL 4080

Mechanisms of Melatonin in Alleviating Alzheimer's Disease

Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J.

Curr Neuropharmacol. 2017;15(7):1010-1031. doi: 10.2174/1570159X15666170313123454.

The protective role of plant biophenols in mechanisms of Alzheimer's disease

Omar SH, Scott CJ, Hamlin AS, Obied HK.

J Nutr Biochem. 2017 Sep;47:1-20. doi: 10.1016/j.jnutbio.2017.02.016. Epub 2017 Mar 3.

Epileptic activity in Alzheimer's disease: causes and clinical relevance

Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL.

Lancet Neurol. 2017 Apr;16(4):311-322. doi: 10.1016/S1474-4422(17)30044-3.

Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease

Olasehinde TA, Olaniran AO, Okoh AI.

Molecules. 2017 Mar 18;22(3):480. doi: 10.3390/molecules22030480.

Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease

Faustino C, Rijo P, Reis CP.

Pharmacol Res. 2017 Jun;120:68-87. doi: 10.1016/j.phrs.2017.03.020. Epub 2017 Mar 27.

Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G.

Curr Alzheimer Res. 2017;14(11):1155-1163. doi: 10.2174/1567205014666170329113007.

Preclinical to phase II amyloid beta (A(β)) peptide modulators under investigation for Alzheimer's disease

Parsons CG, Rammes G.

Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832.

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li Q, Yang H, Chen Y, Sun H.

Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

Alzheimer's disease: where next for anti-amyloid therapies?

Hardy J, De Strooper B.

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials

Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, AlSafadi AM.

BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

Editorial (Thematic Issue: Hybrid Compounds as Multitarget Agents in Medicinal Chemistry - Part II)

Scotti L, Mendonça-Junior FJ, Scotti MT.

Curr Top Med Chem. 2017;17(9):957-958. doi: 10.2174/156802661709170213205211.

Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease

Gonzalez B, Abud EM, Abud AM, Poon WW, Gylys KH.

Neurol Clin. 2017 May;35(2):175-190. doi: 10.1016/j.ncl.2017.01.001.

Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease

Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, Sharma RK, Agrawal M, Mishra A, Dua K.

CNS Neurosci Ther. 2017 Jun;23(6):457-461. doi: 10.1111/cns.12696. Epub 2017 Apr 17.

Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

de Matos AM, de Macedo MP, Rauter AP.

Med Res Rev. 2018 Jan;38(1):261-324. doi: 10.1002/med.21440. Epub 2017 Apr 19.

Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment

Fessel WJ.

Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias